Table 1 Characteristics, treatment and outcome of the five transplanted patients with H1N1 infection in the study
From: The impact of novel influenza A (H1N1) after hematopoietic SCT
Case | Age/ gender | Diagnosis | Type of matched donor | Time from transplant (months) | Conditioning regimens a | Previous GVHD | Immuno- suppression at the time of H1N1 | Duration of immuno- suppression | Lower respiratory tract infection | Co-infection with other pathogen | Treatment (days) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 51/M | ALL | Related | 19 | Flu/Bu | Yes | None | NA | Yes | No | Oseltamivir 5 days | Complete resolution |
2 | 46/F | Myelofibrosis | Unrelated | 7 | Flu/Mel/ATG | Yes | Prednisone Tacrolimus | 5 months 7 months | No | No | Oseltamivir 5 days | Complete resolution |
3 | 23/M | Lymphoblastic lymphoma | Related | 12 | TBI/Cy/ VP-16 | Yes | Tacrolimus | 2 months | No | No | Oseltamivir 5 days | Complete resolution |
4 | 56/F | MDS | Related | 18 | Flu/Bu | Yes | Prednisone MMF Tacrolimus | 2 months 13 months 1 month | Yes | Yes | Oseltamivir 14 days Peramivir 10 days | Death |
5 | 53/F | AML | Autologous | 3 | Flu/Bu | NA | NA | NA | Yes | No | Oseltamivir 5 days | Complete resolution |
